Considerations of heterogeneity in clinical trials for hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Considerations of heterogeneity in clinical trials for hepatocellular carcinoma

Published:2019-05-27 Issue:7 Volume:13 Page:615-621
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Liu Tsung-Hao¹²³,Shao Yu-Yun²³⁴,Lu Li-Chun²³⁴,Shen Ying-Chun²³,Hsu Chiun²³,Lin Zhong-Zhe²³⁴,Hsu Chih-Hung²³⁴,Cheng Ann-Lii²⁵³⁴

Affiliation:

1. Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan

2. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

3. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan

4. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan

5. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Funder

was not funded

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2019.1621165

Reference71 articles.

1. Intratumor Heterogeneity in Hepatocellular Carcinoma

2. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

4. A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6

5. Treatment of intermediate-stage hepatocellular carcinoma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety;Journal of the Formosan Medical Association;2022-12

2. Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study;Anticancer Research;2022-08-23

3. A novel prognostic signature based on four glycolysis‐related genes predicts survival and clinical risk of hepatocellular carcinoma;Journal of Clinical Laboratory Analysis;2021-09-15

4. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan;Journal of the Formosan Medical Association;2021-04

5. Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics;Experimental and Molecular Pathology;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3